{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T22:05:28Z","timestamp":1792101928377,"version":"4.4.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T00:00:00Z","timestamp":1765584000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"The Natural Science Foundation of Shandong Province"},{"name":"People\u2019s Livelihood Science and Technology Project of Qingdao"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-32218-0","type":"journal-article","created":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T08:14:27Z","timestamp":1765613667000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["E2F1-mediated PKMYT1 upregulation promotes prostate cancer progression by inhibiting the PPAR signaling pathway"],"prefix":"10.1038","volume":"16","author":[{"given":"Zengshun","family":"Kou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxi","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuaizhi","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi\u2019ang","family":"Si","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,13]]},"reference":[{"issue":"1","key":"32218_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel, R. L., Miller, K. D., Fuchs, H. E. & Jemal, A. Cancer statistics, 2022. Cancer J. Clin. 72 (1), 7\u201333 (2022).","journal-title":"Cancer J. Clin."},{"issue":"1","key":"32218_CR2","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41391-018-0079-0","volume":"22","author":"ED Crawford","year":"2019","unstructured":"Crawford, E. D. et al. Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerations. Prostate Cancer Prostatic Dis. 22 (1), 24\u201338 (2019).","journal-title":"Prostate Cancer Prostatic Dis."},{"issue":"2","key":"32218_CR3","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.eururo.2020.09.042","volume":"79","author":"N Mottet","year":"2021","unstructured":"Mottet, N. et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and local treatment with curative intent. Eur. Urol. 79 (2), 243\u2013262 (2021).","journal-title":"Eur. Urol."},{"issue":"1","key":"32218_CR4","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s13045-020-00959-2","volume":"13","author":"A di Ghelli Luserna","year":"2020","unstructured":"di Ghelli Luserna, A., Cerchione, C., Martinelli, G. & Simonetti, G. A WEE1 family business: regulation of mitosis, cancer progression, and therapeutic target. J. Hematol. Oncol. 13 (1), 126 (2020).","journal-title":"J. Hematol. Oncol."},{"issue":"12","key":"32218_CR5","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.3390\/molecules22122045","volume":"22","author":"M Schmidt","year":"2017","unstructured":"Schmidt, M. et al. Regulation of G2\/M transition by Inhibition of WEE1 and PKMYT1 kinases. Molecules 22(12), 2045 (2017).","journal-title":"Molecules"},{"issue":"6","key":"32218_CR6","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/j.ccell.2021.03.010","volume":"39","author":"JM Suski","year":"2021","unstructured":"Suski, J. M., Braun, M., Strmiska, V. & Sicinski, P. Targeting cell-cycle machinery in cancer. Cancer cell. 39 (6), 759\u2013778 (2021).","journal-title":"Cancer cell."},{"issue":"11","key":"32218_CR7","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1021\/acsmedchemlett.4c00486","volume":"15","author":"RW Sabnis","year":"2024","unstructured":"Sabnis, R. W. Novel Indazole compounds as PKMYT1 kinase inhibitors for treating cancer. ACS Med. Chem. Lett. 15 (11), 1810\u20131811 (2024).","journal-title":"ACS Med. Chem. Lett."},{"issue":"1","key":"32218_CR8","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s12943-022-01522-y","volume":"21","author":"Y Hu","year":"2022","unstructured":"Hu, Y. et al. Demethylase ALKBH5 suppresses invasion of gastric cancer via PKMYT1 m6A modification. Mol. Cancer. 21 (1), 34 (2022).","journal-title":"Mol. Cancer"},{"issue":"1","key":"32218_CR9","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s12943-021-01469-6","volume":"20","author":"Y He","year":"2021","unstructured":"He, Y. et al. LncRNA PKMYT1AR promotes cancer stem cell maintenance in non-small cell lung cancer via activating Wnt signaling pathway. Mol. Cancer. 20 (1), 156 (2021).","journal-title":"Mol. Cancer"},{"key":"32218_CR10","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.cytogfr.2023.10.001","volume":"75","author":"D Wekking","year":"2024","unstructured":"Wekking, D. et al. CDK4\/6 Inhibition in hormone receptor-positive\/HER2-negative breast cancer: biological and clinical aspects. Cytokine Growth Factor Rev. 75, 57\u201364 (2024).","journal-title":"Cytokine Growth Factor Rev."},{"issue":"15","key":"32218_CR11","doi-asserted-by":"publisher","first-page":"10251","DOI":"10.1021\/acs.jmedchem.2c00552","volume":"65","author":"J Szychowski","year":"2022","unstructured":"Szychowski, J. et al. Discovery of an orally bioavailable and selective PKMYT1 Inhibitor, RP-6306. J. Med. Chem. 65 (15), 10251\u201310284 (2022).","journal-title":"J. Med. Chem."},{"issue":"1","key":"32218_CR12","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1186\/s12885-024-13109-5","volume":"24","author":"W Fukumoto","year":"2024","unstructured":"Fukumoto, W. et al. Development of a novel treatment based on PKMYT1 Inhibition for cisplatin-resistant bladder cancer with miR-424-5p-dependent Cyclin E1 amplification. BMC Cancer. 24 (1), 1333 (2024).","journal-title":"BMC Cancer"},{"key":"32218_CR13","doi-asserted-by":"publisher","first-page":"144608","DOI":"10.1016\/j.gene.2020.144608","volume":"744","author":"J Wang","year":"2020","unstructured":"Wang, J. et al. PKMYT1 is associated with prostate cancer malignancy and May serve as a therapeutic target. Gene 744, 144608 (2020).","journal-title":"Gene"},{"issue":"1","key":"32218_CR14","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s12943-024-02205-6","volume":"24","author":"K Huang","year":"2025","unstructured":"Huang, K. et al. Tumor metabolic regulators: key drivers of metabolic reprogramming and the promising targets in cancer therapy. Mol. Cancer. 24 (1), 7 (2025).","journal-title":"Mol. Cancer"},{"issue":"2","key":"32218_CR15","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.clnu.2023.12.005","volume":"43","author":"Y Li","year":"2024","unstructured":"Li, Y. et al. Peroxisome proliferator-activated receptors: A key link between lipid metabolism and cancer progression. Clin. Nutr. 43 (2), 332\u2013345 (2024).","journal-title":"Clin. Nutr."},{"key":"32218_CR16","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.freeradbiomed.2024.05.030","volume":"221","author":"M Shiota","year":"2024","unstructured":"Shiota, M. et al. Oxidative stress in peroxisomes induced by androgen receptor Inhibition through peroxisome proliferator-activated receptor promotes enzalutamide resistance in prostate cancer. Free Radic. Biol. Med. 221, 81\u201388 (2024).","journal-title":"Free Radic. Biol. Med."},{"issue":"2","key":"32218_CR17","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1158\/0008-5472.CAN-17-0908","volume":"78","author":"N Mart\u00edn-Mart\u00edn","year":"2018","unstructured":"Mart\u00edn-Mart\u00edn, N. et al. PPAR\u03b4 elicits Ligand-Independent repression of trefoil factor family to limit prostate cancer growth. Cancer Res. 78 (2), 399\u2013409 (2018).","journal-title":"Cancer Res."},{"issue":"1","key":"32218_CR18","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.metabol.2004.07.010","volume":"54","author":"M Inaba","year":"2005","unstructured":"Inaba, M. et al. Marked hyperglycemia after androgen-deprivation therapy for prostate cancer and usefulness of Pioglitazone for its treatment. Metab. Clin. Exp. 54 (1), 55\u201359 (2005).","journal-title":"Metab. Clin. Exp."},{"key":"32218_CR19","doi-asserted-by":"publisher","first-page":"16018","DOI":"10.1038\/srep16018","volume":"5","author":"MM Mortensen","year":"2015","unstructured":"Mortensen, M. M. et al. Expression profiling of prostate cancer tissue delineates genes associated with recurrence after prostatectomy. Sci. Rep. 5, 16018 (2015).","journal-title":"Sci. Rep."},{"issue":"17","key":"32218_CR20","first-page":"e2206889","volume":"10","author":"D Wang","year":"2023","unstructured":"Wang, D. et al. IL-1\u03b2 is an Androgen-Responsive target in macrophages for immunotherapy of prostate Cancer. Advanced science (Weinheim. Baden-Wurttemberg Germany). 10 (17), e2206889 (2023).","journal-title":"Baden-Wurttemberg Germany)"},{"issue":"4","key":"32218_CR21","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/j.immuni.2013.10.003","volume":"39","author":"G Bindea","year":"2013","unstructured":"Bindea, G. et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity 39 (4), 782\u2013795 (2013).","journal-title":"Immunity"},{"issue":"7","key":"32218_CR22","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/s41587-019-0114-2","volume":"37","author":"AM Newman","year":"2019","unstructured":"Newman, A. M. et al. Determining cell type abundance and expression from bulk tissues with digital cytometry. Nat. Biotechnol. 37 (7), 773\u2013782 (2019).","journal-title":"Nat. Biotechnol."},{"issue":"2","key":"32218_CR23","doi-asserted-by":"publisher","first-page":"333","DOI":"10.3390\/life13020333","volume":"13","author":"JK Messex","year":"2023","unstructured":"Messex, J. K. & Liou, G. Y. Impact of immune cells in the tumor microenvironment of prostate cancer metastasis. Life 13(2), 333 (2023).","journal-title":"Life"},{"issue":"1","key":"32218_CR24","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41572-020-00243-0","volume":"7","author":"RJ Rebello","year":"2021","unstructured":"Rebello, R. J. et al. Prostate cancer. Nat. Reviews Disease Primers. 7 (1), 9 (2021).","journal-title":"Nat. Reviews Disease Primers"},{"key":"32218_CR25","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.canlet.2021.10.027","volume":"525","author":"C Wang","year":"2022","unstructured":"Wang, C., Zhang, Y. & Gao, W. Q. The evolving role of immune cells in prostate cancer. Cancer Lett. 525, 9\u201321 (2022).","journal-title":"Cancer Lett."},{"issue":"12","key":"32218_CR26","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.3390\/ph17121589","volume":"17","author":"J Park","year":"2024","unstructured":"Park, J. & Kim, J. CRISPR\/Cas9 technology providing the therapeutic landscape of metastatic prostate cancer. Pharmaceuticals 17(12), 1589 (2024).","journal-title":"Pharmaceuticals"},{"key":"32218_CR27","doi-asserted-by":"publisher","first-page":"102766","DOI":"10.1016\/j.ctrv.2024.102766","volume":"128","author":"A Guida","year":"2024","unstructured":"Guida, A. et al. The 5-WS of targeting DNA-damage repair (DDR) pathways in prostate cancer. Cancer Treat. Rev. 128, 102766 (2024).","journal-title":"Cancer Treat. Rev."},{"key":"32218_CR28","doi-asserted-by":"publisher","first-page":"103199","DOI":"10.1016\/j.critrevonc.2020.103199","volume":"157","author":"N Brighi","year":"2021","unstructured":"Brighi, N. et al. The cyclin-dependent kinases pathway as a target for prostate cancer treatment: rationale and future perspectives. Crit. Rev. Oncol. Hematol. 157, 103199 (2021).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"32218_CR29","doi-asserted-by":"publisher","first-page":"955476","DOI":"10.3389\/fimmu.2022.955476","volume":"13","author":"S Pal","year":"2022","unstructured":"Pal, S., Sharma, A., Mathew, S. P. & Jaganathan, B. G. Targeting cancer-specific metabolic pathways for developing novel cancer therapeutics. Front. Immunol. 13, 955476 (2022).","journal-title":"Front. Immunol."},{"issue":"1","key":"32218_CR30","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s13059-015-0690-5","volume":"16","author":"L Szabo","year":"2015","unstructured":"Szabo, L. et al. Statistically based splicing detection reveals neural enrichment and tissue-specific induction of circular RNA during human fetal development. Genome Biol. 16 (1), 126 (2015).","journal-title":"Genome Biol."},{"key":"32218_CR31","doi-asserted-by":"publisher","first-page":"1491497","DOI":"10.3389\/fphar.2024.1491497","volume":"15","author":"Y Yang","year":"2024","unstructured":"Yang, Y. et al. Discovery of novel and highly potent dual-targeting PKMYT1\/HDAC2 inhibitors for hepatocellular carcinoma through structure-based virtual screening and biological evaluation. Front. Pharmacol. 15, 1491497 (2024).","journal-title":"Front. Pharmacol."},{"issue":"6","key":"32218_CR32","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1002\/pros.24315","volume":"82","author":"B Ozbek","year":"2022","unstructured":"Ozbek, B. et al. Multiplex immunohistochemical phenotyping of T cells in primary prostate cancer. Prostate 82 (6), 706\u2013722 (2022).","journal-title":"Prostate"},{"issue":"12","key":"32218_CR33","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1038\/s41590-024-02007-4","volume":"25","author":"H Nagashima","year":"2024","unstructured":"Nagashima, H. et al. Remodeling of Il4-Il13-Il5 locus underlies selective gene expression. Nat. Immunol. 25 (12), 2220\u20132233 (2024).","journal-title":"Nat. Immunol."},{"issue":"7","key":"32218_CR34","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.trecan.2019.05.008","volume":"5","author":"S Laudato","year":"2019","unstructured":"Laudato, S., Aparicio, A. & Giancotti, F. G. Clonal evolution and epithelial plasticity in the emergence of AR-Independent prostate carcinoma. Trends Cancer. 5 (7), 440\u2013455 (2019).","journal-title":"Trends Cancer"},{"issue":"24","key":"32218_CR35","doi-asserted-by":"publisher","first-page":"11897","DOI":"10.1158\/0008-5472.CAN-06-2497","volume":"66","author":"JN Davis","year":"2006","unstructured":"Davis, J. N. et al. Elevated E2F1 inhibits transcription of the androgen receptor in metastatic hormone-resistant prostate cancer. Cancer Res. 66 (24), 11897\u201311906 (2006).","journal-title":"Cancer Res."},{"issue":"4","key":"32218_CR36","doi-asserted-by":"publisher","first-page":"450","DOI":"10.3390\/genes15040450","volume":"15","author":"KCS Silva","year":"2024","unstructured":"Silva, K. C. S. et al. Transcription factors in prostate cancer: insights for disease development and diagnostic and therapeutic approaches. Genes 15(4), 450 (2024).","journal-title":"Genes"},{"issue":"1","key":"32218_CR37","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/s41420-023-01341-0","volume":"9","author":"K Guo","year":"2023","unstructured":"Guo, K. et al. HMMR promotes prostate cancer proliferation and metastasis via AURKA\/mTORC2\/E2F1 positive feedback loop. Cell. Death Discovery. 9 (1), 48 (2023).","journal-title":"Cell. Death Discovery"},{"issue":"5","key":"32218_CR38","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.14336\/AD.2023.0202","volume":"14","author":"Z Song","year":"2023","unstructured":"Song, Z. et al. Overexpression of RACGAP1 by E2F1 promotes neuroendocrine differentiation of prostate cancer by stabilizing EZH2 expression. Aging Disease. 14 (5), 1757\u20131774 (2023).","journal-title":"Aging Disease"},{"key":"32218_CR39","doi-asserted-by":"publisher","first-page":"117147","DOI":"10.1016\/j.biopha.2024.117147","volume":"178","author":"M Sun","year":"2024","unstructured":"Sun, M. et al. Posttranslational modifications of E2F family members in the physiological state and in cancer: Roles, mechanisms and therapeutic targets. Biomed. pharmacotherapy = Biomedecine Pharmacotherapie. 178, 117147 (2024).","journal-title":"Biomed. pharmacotherapy = Biomedecine Pharmacotherapie"},{"issue":"1","key":"32218_CR40","doi-asserted-by":"publisher","first-page":"101890","DOI":"10.1016\/j.xcrm.2024.101890","volume":"6","author":"O Hawsawi","year":"2024","unstructured":"Hawsawi, O. et al. Mitochondrial uncouplers inhibit oncogenic E2F1 activity and prostate cancer growth. Cell. Rep. Med. 6(1), 101890 (2024).","journal-title":"Cell. Rep. Med."},{"key":"32218_CR41","doi-asserted-by":"publisher","first-page":"176304","DOI":"10.1016\/j.ejphar.2023.176304","volume":"964","author":"Y Zhang","year":"2024","unstructured":"Zhang, Y. et al. Roles of PPAR activation in cancer therapeutic resistance: implications for combination therapy and drug development. Eur. J. Pharmacol. 964, 176304 (2024).","journal-title":"Eur. J. Pharmacol."},{"issue":"2","key":"32218_CR42","doi-asserted-by":"publisher","first-page":"183","DOI":"10.3390\/metabo13020183","volume":"13","author":"UR Wanjari","year":"2023","unstructured":"Wanjari, U. R. et al. Role of metabolism and metabolic pathways in prostate cancer. Metabolites 13(2), 183 (2023).","journal-title":"Metabolites"},{"issue":"3","key":"32218_CR43","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1002\/ptr.8115","volume":"38","author":"Y Park","year":"2024","unstructured":"Park, Y. et al. Inhibition of Glycolysis and SIRT1\/GLUT1 signaling ameliorates the apoptotic effect of leptosidin in prostate cancer cells. Phytother. Res. 38 (3), 1235\u20131244 (2024).","journal-title":"Phytother. Res."},{"issue":"2","key":"32218_CR44","doi-asserted-by":"publisher","first-page":"910","DOI":"10.3390\/ijms24020910","volume":"24","author":"F Lasorsa","year":"2023","unstructured":"Lasorsa, F. et al. Emerging hallmarks of metabolic reprogramming in prostate cancer. Int. J. Mol. Sci. 24(2), 910 (2023).","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"32218_CR45","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1038\/s41416-022-02096-8","volume":"128","author":"A Hartley","year":"2023","unstructured":"Hartley, A. & Ahmad, I. The role of PPAR\u03b3 in prostate cancer development and progression. Br. J. Cancer. 128 (6), 940\u2013945 (2023).","journal-title":"Br. J. Cancer"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-32218-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-32218-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-32218-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T02:03:39Z","timestamp":1769220219000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-32218-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,13]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["32218"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-32218-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,13]]},"assertion":[{"value":"30 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The subject followed the Declaration of Helsinki, and was approved by the Ethical Review Committee of Qingdao University (No: QDU-AEC-2024697).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}}],"article-number":"2477"}}